Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective long-term cardiac magnetic resonance imaging study - PubMed (original) (raw)
Clinical Trial
. 2009 Jul;95(13):1103-7.
doi: 10.1136/hrt.2008.162800. Epub 2009 Apr 15.
Affiliations
- PMID: 19372091
- DOI: 10.1136/hrt.2008.162800
Clinical Trial
Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective long-term cardiac magnetic resonance imaging study
M Imbriaco et al. Heart. 2009 Jul.
Abstract
Background: Anderson-Fabry disease is a multisystem X linked disorder of lipid metabolism frequently associated with cardiac symptoms, including left ventricular (LV) hypertrophy gradually impairing cardiac function. Evidence showing that enzyme-replacement therapy (ERT) can be effective in reducing LV hypertrophy and improving myocardial function in the long term is limited.
Objective: This study aimed to assess the long-term effects of ERT with recombinant alpha-galactosidase A (agalsidase beta, Fabrazyme) on LV function and myocardial signal intensity in 11 patients with Anderson-Fabry disease.
Patients: Eleven patients (eight males, three females) with varying stages of genetically confirmed Anderson-Fabry disease were examined by means of physical examination and magnetic resonance imaging before ERT with agalsidase beta at 1 mg/kg every other week (study 1) and after a mean treatment duration of 45 months (study 2).
Results: At 45 months of treatment, LV mass and LV wall thickness had significantly reduced: 188 (SD 60) g versus 153 (47) g, and 16 (4) mm versus 14 (4) mm, respectively. Furthermore, a significant reduction in myocardial T2 relaxation times was noted in all myocardial regions, that is, interventricular septum 80 (5) ms versus 66 (8) ms, apex 79 (10) ms versus 64 (10) ms, and lateral wall 80 (8) ms versus 65 (16) ms. Changes in LV ejection fraction were not significant. Amelioration of clinical symptoms was observed in all patients.
Conclusions: Long-term therapy with agalsidase beta at 1 mg/kg every 2 weeks was effective in significantly reducing LV hypertrophy, improving overall cardiac performance and ameliorating clinical symptoms in patients with Anderson-Fabry disease.
Similar articles
- Role of cardiac MRI in evaluating patients with Anderson-Fabry disease: assessing cardiac effects of long-term enzyme replacement therapy.
Messalli G, Imbriaco M, Avitabile G, Russo R, Iodice D, Spinelli L, Dellegrottaglie S, Cademartiri F, Salvatore M, Pisani A. Messalli G, et al. Radiol Med. 2012 Feb;117(1):19-28. doi: 10.1007/s11547-011-0710-9. Epub 2011 Jul 9. Radiol Med. 2012. PMID: 21744250 English, Italian. - Myocardial Storage, Inflammation, and Cardiac Phenotype in Fabry Disease After One Year of Enzyme Replacement Therapy.
Nordin S, Kozor R, Vijapurapu R, Augusto JB, Knott KD, Captur G, Treibel TA, Ramaswami U, Tchan M, Geberhiwot T, Steeds RP, Hughes DA, Moon JC. Nordin S, et al. Circ Cardiovasc Imaging. 2019 Dec;12(12):e009430. doi: 10.1161/CIRCIMAGING.119.009430. Epub 2019 Dec 12. Circ Cardiovasc Imaging. 2019. PMID: 31826677 Free PMC article. - Long-term changes in arterial structure and function and left ventricular geometry after enzyme replacement therapy in patients affected with Fabry disease.
Collin C, Briet M, Tran TC, Beaussier H, Benistan K, Bensalah M, Mousseaux E, Froissart M, Bozec E, Laurent S, Boutouyrie P, Germain DP. Collin C, et al. Eur J Prev Cardiol. 2012 Feb;19(1):43-54. doi: 10.1177/1741826710391118. Epub 2011 Mar 4. Eur J Prev Cardiol. 2012. PMID: 21450622 - Agalsidase alfa: a review of its use in the management of Fabry disease.
Keating GM. Keating GM. BioDrugs. 2012 Oct 1;26(5):335-54. doi: 10.2165/11209690-000000000-00000. BioDrugs. 2012. PMID: 22946754 Review. - Enzyme replacement therapy for Anderson-Fabry disease.
El Dib R, Gomaa H, Carvalho RP, Camargo SE, Bazan R, Barretti P, Barreto FC. El Dib R, et al. Cochrane Database Syst Rev. 2016 Jul 25;7(7):CD006663. doi: 10.1002/14651858.CD006663.pub4. Cochrane Database Syst Rev. 2016. PMID: 27454104 Free PMC article. Review.
Cited by
- Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients with Fabry Disease.
Lenders M, Brand E. Lenders M, et al. J Am Soc Nephrol. 2018 Sep;29(9):2265-2278. doi: 10.1681/ASN.2018030329. Epub 2018 Aug 9. J Am Soc Nephrol. 2018. PMID: 30093456 Free PMC article. Review. No abstract available. - Cardiac Magnetic Resonance in Fabry Disease: Morphological, Functional, and Tissue Features.
Aquaro GD, De Gori C, Faggioni L, Parisella ML, Aringhieri G, Cioni D, Lencioni R, Neri E. Aquaro GD, et al. Diagnostics (Basel). 2022 Nov 1;12(11):2652. doi: 10.3390/diagnostics12112652. Diagnostics (Basel). 2022. PMID: 36359495 Free PMC article. Review. - Effects of Enzyme Replacement Therapy on Cardiac MRI Findings in Fabry Disease: A Systematic Review and Meta-Analysis.
Figliozzi S, Kollia E, Simistiras A, Camporeale A, Stankowski K, Masci PG, Mavraganis G, Lombardi M, Condorelli G, Francone M, Pieroni M, Georgiopoulos G. Figliozzi S, et al. Radiol Cardiothorac Imaging. 2024 Jun;6(3):e230154. doi: 10.1148/ryct.230154. Radiol Cardiothorac Imaging. 2024. PMID: 38842453 Free PMC article. - The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy.
Feriozzi S, Torras J, Cybulla M, Nicholls K, Sunder-Plassmann G, West M; FOS Investigators. Feriozzi S, et al. Clin J Am Soc Nephrol. 2012 Jan;7(1):60-9. doi: 10.2215/CJN.03130411. Clin J Am Soc Nephrol. 2012. PMID: 22246281 Free PMC article. - Effects of switching from agalsidase Beta to agalsidase alfa in 10 patients with anderson-fabry disease.
Pisani A, Spinelli L, Visciano B, Capuano I, Sabbatini M, Riccio E, Messalli G, Imbriaco M. Pisani A, et al. JIMD Rep. 2013;9:41-48. doi: 10.1007/8904_2012_177. Epub 2012 Oct 21. JIMD Rep. 2013. PMID: 23430546 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous